Little is known of the effects of obesity on ertapenem drug disposition and
pharmacodynamics. Thirty healthy volunteers in three body mass index (BMI) groups (10 per …

Study Objective To compare ertapenem pharmacokinetics, pharmacodynamics, and
tolerability when administered as a rapid 5‐minute infusion to the standard 30‐minute …

Ertapenem (INVANZ) is a new once-a-day parenteral β-lactam antimicrobial shown to be
effective as a single agent for treatment of various community-acquired and mixed infections …

Ertapenem, a parenteral broad-spectrum 1-β-methyl-carbapenem, was licensed 5 years ago
for clinical practice in the US and Europe. The substance has a good in vitro activity against …

Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral β-lactam antibiotic recently
licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has …

Objectives: Ertapenem is FDA approved for the treatment of skin and skin-structure
infections (SSSI), but its in vivo penetration into the interstitial space of soft tissues is …

Ertapenem is a new once-a-day parenteral carbapenem antimicrobial agent. The
pharmacokinetics of unbound and total concentrations of ertapenem in plasma were …

We conducted a prospective study of 18 adult volunteers (male-to-female ratio of 1) whose
body mass index fell into categories of< 25, 25 to 40, or> 40 kg/m2, who received a single …

The pharmacodynamic profile of ertapenem was evaluated in a neutropenic mouse thigh
infection model. Extended-spectrum beta-lactamase (ESBL)-positive and ESBL-negative …

Ertapenem (INVANZ) is a new once-a-day parental β-lactam antimicrobial agent that has
been shown to be highly effective as a single agent for treatment of various community …